CME vs. Morningstar: Which Financial Stock Is a Better Buy in 2026?

CME generated nearly $6.5B of fiscal 2025 revenue (+6.4%), approximately $4.0B of net income and a sector-leading 62% net margin, versus Morningstar's $2.4B of revenue (+7.5%) and $374.2M of net income. Morningstar screens cheaper at a 15.5x forward P/E and 2.9x sales, compared with CME at 22.5x and 15.2x, though CME has substantially lower leverage (0.1x debt-to-equity versus 1.2x). The analysis cautiously favors CME for its high-margin, activity-driven exchange model and dividend, while noting its premium valuation and that neither stock is viewed as especially compelling.

Analysis

The relevant distinction is not simply exchange margin versus data subscription revenue: CME monetizes realized volatility, rate-policy uncertainty, and hedging intensity, while MORN must convert product innovation into net retention against better-capitalized data incumbents. CME's earnings resilience can therefore mask a cyclical volume risk if rate and equity volatility normalize simultaneously; its premium leaves limited tolerance for a sustained decline in average daily volume or transaction-fee yield. ICE and CBOE offer cleaner relative alternatives if their product mixes capture the same volatility backdrop at lower embedded expectations.

MORN's valuation discount is only attractive if its software/data segments can accelerate organic growth without incremental leverage or AI-related pricing pressure. AI distribution can expand usage, but it also risks commoditizing basic research workflows; the value accrues to providers with proprietary, workflow-critical datasets and pricing power, favoring SPGI and MSCI unless MORN demonstrates improving retention, seat expansion, or margin conversion. The key 1-3 month catalyst is quarterly segment-level organic growth and guidance, not a generic AI partnership announcement.

Consensus likely overstates CME's all-weather characteristics: derivatives volumes are not uniformly countercyclical, and a low-volatility soft landing could compress both rate and equity hedging activity. Conversely, the market may be underweighting MORN's operating leverage if subscription growth reaccelerates, but the balance-sheet profile means that thesis requires evidence before underwriting multiple expansion. This is a low-impact comparison article; no standalone directional catalyst is established.

Key Decisions for Investors

• Maintain CME as a quality core holding only if implied volatility and CME average daily volume remain supportive; avoid adding at the current premium absent a post-earnings volume/guidance beat. Thesis fails if rate and equity product volumes decline for two consecutive reported months while pricing yield is flat-to-down.
• Watch MORN for a tactical 6-12 month long only after confirmation of accelerating organic subscription/software growth and stable net leverage; target a rerating toward data-peer multiples, with downside controlled by exiting on a guidance cut or evidence of AI-driven pricing/retention pressure.
• For a relative-value expression, consider long MORN / short CME only after MORN reports a clear growth inflection and CME volume trends soften. The trade has asymmetric risk because CME can outperform sharply during a volatility shock; size modestly and use a stop if the relative spread breaks materially against entry.
• Prefer SPGI or MSCI over MORN for broad data-and-index exposure until MORN discloses measurable AI monetization, retention, and margin benefits. Monitor asset-manager flows and index-linked AUM growth as the higher-frequency indicators of pricing and earnings durability.
• Do not initiate FLUT exposure on the prediction-market linkage alone; monitor regulatory approvals, customer economics, and any revenue-sharing disclosures before assigning material value to the venture.